Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results

 
• By Joseph Haas

Larger of two doses of the NGF inhibitor hit two efficacy endpoints, but the rate of joint health outcomes on a composite measure was higher than control by a statistically significant margin.

Research analyst adding reagent to drug to keep tracking chemical reaction - Image
Lilly and Pfizer's latest clinical data for tanezumab did not de-risk the drug's safety

More from Clinical Trials

More from R&D